GlassScriptPhysician profile
Timothy C Mangrum
NPI 1124067533
$10,514.92
in general payments reported to CMS, 2019-2025
32 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $1,214 · 2021: $1,376 · 2022: $1,605 · 2023: $1,597 · 2024: $1,613 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,732.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,687.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,160.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,091.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $998.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $944.90 | 2019-2025 | |
| Abbvie INC. | $860.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $287.30 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $273.57 | 2019-2025 | |
| Abbott Laboratories | $234.46 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $228.98 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.45 | 2021-2025 | Jardiance, Jascayd, Synjardy |
| Glaxosmithkline, LLC. | $197.24 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $141.89 | 2022-2024 | |
| Allergan, INC. | $126.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $120.78 | 2019-2023 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $116.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $115.56 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.75 | 2019-2021 | |
| Sensible Medical Innovations INC | $96.92 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $76.15 | 2019 | |
| Sanofi Pasteur INC. | $66.88 | 2019-2022 | |
| Esperion Therapeutics, INC. | $64.03 | 2021 | |
| Amarin Pharma, INC. | $60.61 | 2019-2021 | |
| Axsome Therapeutics, INC. | $44.71 | 2025 | Symbravo |
| Xeris Pharmaceuticals, INC. | $35.78 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $27.47 | 2023 | Vyepti |
| Orphalan INC | $25.77 | 2025 | Cuvrior |
| Shire North American Group INC | $24.69 | 2019 | |
| Radius Health, INC. | $24.12 | 2023 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $20.08 | 2022 | |
| Antares Pharma, INC. | $18.70 | 2023 | Tlando, Nocdurna, Xyosted |
| Dynavax Technologies Corporation | $16.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mangrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.